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Conclusion: In our study, both new generation DESs, ZES and EES were similarly
effective and safe up to 1 year following routine PCI in Asian population
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Background: The TAXUS Element (ION) paclitaxel-eluting stent (PES) uses the same
polymer and drug as the TAXUS Liberté PES, but with a novel thin (81μM) strut
platinum chromium metal alloy cell design. We present 2-year data comparing clinical
outcomes between the ION and TAXUS Liberté PES.
Methods: Patient-level data from 2298 subjects treated with PES were pooled from
the TAXUS ATLAS (TAXUS Liberté Stent) and PERSEUS (ION Stent) trials and
propensity matched 1:1 to adjust for significant baseline differences.
Results: Two-year MACE was significantly lower in the ION versus the TAXUS
Liberté group, with and without propensity matching (Table), driven largely by a
reduction in non-Q-wave MI. Numerical reductions in non-Q-wave MI were seen in
both the periprocedural (2.1% vs. 1.3%, P=0.12 unadjusted; 2.4% vs. 0.8%, P=0.02
matched) and discharge – 2 year timeframes (1.3% vs. 0.5%, P=0.07 unadjusted; 1.2%
vs. 0.6%, P=0.28 matched). Non-Q-wave MI was significantly lower with ION in
patients treated with single stents (3.1% vs. 1.4%, P=0.01 unadjusted; 3.4% vs. 1.4%,
P=0.02 matched) but not in patients treated with multiple stents, although sample sizes
were small (5.9% [N=85] vs. 5.6% [N=90], P=0.94 unadjusted; 7.7% [N=39] vs. 1.8%
[N=55], P=0.17 matched). Stent thrombosis (ARC definite/probable) was numerically
less frequent following ION use.
Conclusion: In this exploratory post hoc analysis, ION was associated with lower 2-
year MACE than TAXUS Liberté, driven mainly by reduced non-Q-wave MI. These
differences may be explained by thinner struts and modified cell design in the ION
stent, although evolution in adjunctive therapies and stenting technique may also
contribute.
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Background: Due to the limited distensibility of the everolimus-eluting bioresorbable
vascular scaffold (ABSORB) compared to metallic platform stents, quantitative
coronary arteriography (QCA) is a mandatory requirement for ABSORB deployment
in ABSORB EXTEND. Visual assessment of vessel size in the ABSORB Cohort B
study often lead to under (Fig.) & over-sizing of the 3mm ABSORB in coronary vessels
(recommended vessel diameter ≥2.5-≤3.3mm), with an increased risk of spontaneous
incomplete scaffold apposition post deployment. We report whether mandatory QCA
assessment of vessel size pre-implantation utilising the Dmax & established
interpolated reference vessel diameter (RVD) measurements has improved
device/vessel sizing.
Methods: Pre-implantation post-hoc QCA analyses of all 101 patients from ABSORB
Cohort B (102 lesions) & first consecutive 101 patients (108 lesions) from ABSORB
EXTEND were undertaken by an independent corelab; all patients had a 3mm
ABSORB implanted. Comparative analyses were performed.
Results: Within ABSORB Cohort B a greater no. of over-sized vessels (>3.3mm) were
identified utilizing the Dmax compared to the RVD (17 vessels, 16.7% vs. 3 vessels,
2.9%; p=0.002). Comparative analyses demonstrated a greater no. of appropriate vessel
size selection (75 vessels, 69.4% vs. 48 vessels, 47.1%; p=0.001), a trend towards a
reduction in implantation in small (<2.5mm) vessels (29 vessels, 26.9% vs. 40 vessels,
39.2%; p=0.057) & a significant decrease in the implantation in large (>3.3 mm)
vessels (4 vessels, 3.7% vs. 17 vessels, 16.7%; p=0.002) in ABSORB EXTEND.
Bland–Altman plots suggested a good agreement between operator/corelab assessed
Dmax measurements.
3mm BVS implanted in vessel with Dmax 4.42mm
Conclusion: The introduction of mandatory Dmax measurements of vessel size prior
to ABSORB implantation significantly reduced the undersizing of the 3.0mm ABSORB
in large vessels validating the use of this technique in vessel sizing prior to ABSORB
implantation.
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Background: Direct stenting (DS) may potentially reduce vessel trauma,
“geographical miss”, prevent distal embolization and save time/money during PCI.
However, DS is currently performed in < 50%. Among the reasons to pre-dilate, vessel
anatomy (tortuosity and amount of calcification) plays a central role in the operator’s
decision.The Acrobat SOAW (Stent-On-A-Wire) coronary system combines a very-
thin (81 μ) balloon-expandable, Cro-Co stent mounted on a delivery system with a
0.012” integrated guidewire tip (distance from the tip of the wire to the stent is 22mm).
We sought to determine the efficacy of this novel device.
Methods: SVELTE trial is a multicenter(Brazil, Netherlands and Colombia),
prospective, non-randomized, single-arm study of the Acrobat SOAW for the treatment
of de novo coronary lesions no longer than 18mm and located in native vessels of 2.5
to 3.5mm. DS was highly recommended. Patients were oriented to stay on dual anti-
platelet regimen for at least 1 month. Main exclusion criteria were PCI in the setting
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of acute STEMI and bifurcation lesions. All patients were scheduled to undergo
angiographic follow-up at 6 months. The primary endpoint of the study was the
survival-free of MACE (cardiac death, MI and TLR) at 30 days. Secondary endpoints
included 6-month in-stent late lumen loss and binary restenosis.
Results: A total of 46 patients were enrolled with mean age of 63 years old, 76.6% of
male and 21.3% of diabetics. Mean RVD and lesion length were 3.03mm and
12.67mm, respectively. The Acrobat stent was deployed in 100% of the cases (89.6%
of DS) achieving a procedure success rate of 97.8%. Up to 30 days there was no
MACE. Six-month invasive follow-up was so far completed for 42 patients, with an
in-stent late loss of 0.76mm and only 3 cases of ischemia-driven TLR (7.6%). Complete
follow-up data will be available at the meeting.
Conclusion: The Acrobat SOAW may potentially facilitate PCI by reducing time/cost
and minimizing peri-procedural complications. The present trial represents the first-
in-man assessment of this innovative concept.
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Background: Long coronary lesions are associated with high restenosis rates and
adverse clinical outcomes. The platinum chromium PROMUS Element everolimus-
eluting stent (EES, Boston Scientific, Natick, MA) demonstrated noninferior clinical
outcomes compared to the XIENCE V EES (Abbott, Santa Clara, CA) in lesions
≤24mm. The PLATINUM Long Lesion (LL) study assessed results in lesions >24mm.
Methods: Patients had angina pectoris or documented silent ischemia. One de novo
target lesion >24 to ≤34mm long with reference diameter ≥2.50 to ≤4.25mm could be
treated with a 32 or 38mm stent. A lesion in a different epicardial vessel could be treated
with a non-study treatment before the target lesion. The primary endpoint, 12-month
target lesion failure (composite of target vessel related cardiac death/MI and ischemia-
driven target lesion revascularization) in the per-protocol population, was compared
to a performance goal (PG) of 19.4% based on historical outcomes with 32mm
paclitaxel-eluting stents (the only long drug-eluting stent approved in the US when
PLATINUM LL was initiated) in the TAXUS V DN trial. Clinical follow-up is at 1, 6,
12, 18M and annually to 5 years.
Results: 102 patients enrolled at 30 international sites. Table 1 shows baseline
characteristics and outcomes. TLF in the per-protocol population was 3.2% with a one-
sided upper confidence bound of 7.96%, significantly less than the PG (p<0.0001).
Conclusion: The PLATINUM LL results support the safety and efficacy of the 32 and
38mm PROMUS Element stent.
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Background: Durable polymers used for first-generation drug-eluting stents
potentially contribute to persistent inflammation, delayed endothelial healing, and late
stent thrombosis. NOYA is a Co-Cr based sirolimus-eluting stent (SES) with DL-
Polylactide biodegradable polymer (Medfavour Medical, Beijing, China). The present
study aimed to evaluate the efficacy and safety of NOYA stent in treating de novo
coronary artery lesions.
Methods: NOYA I trial was designed to test the non-inferiority of in-stent late loss of
NOYA stent compared to FIREBIRD 2 stent, a widely used SES with durable polymer
in China (MicroPort Medical, Shanghai, China). Subjects with maximum of two de
novo native coronary lesions with DS% >= 70% by visual estimation (Age 18-75,
lesion length <= 30mm, RVD 2.5-4.0mm) were enrolled. The primary endpoint was
in-stent late loss at 9-month. The secondary endpoints were binary restenosis rates at
9-month, major adverse cardiac events (MACE) defined as the composite of cardiac
death, myocardial infarction (MI), or target lesion revascularization (TLR), and
definite/probable stent thrombosis at 12-month.
Results: A total of 300 patients (n=150 in each group) were enrolled from 16 Chinese
centers in the study. Baseline data and procedural results were comparable between
the two groups. The 9-month angiographic follow-up rate was 87.9%. In-stent late loss
was 0.11±0.20mm in NOYA vs. 0.13±0.19mm in FIREBIRD 2 group (non-inferiority
p=0.00000017). In-segment binary restenosis rates were similar in both groups (4.2%
vs. 3.7%, p=0.8028). The rates of MACE, TLR and MI at 12-month were same (4.7%
vs. 4.7%; 2.0% vs. 2.0%; 2.7% vs. 2.7%; respectively). Neither stent thrombosis nor
cardiac death was observed at 12-month.
Conclusion: The primary non-inferiority endpoint of in-stent late loss at 9-month was
met. Longer term follow-up and large scale trial are needed to further evaluate the
newly developed NOYA SES with biodegradable polymer coating. (clinicaltrials.gov
identifier: 01226355)
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Background: Durable polymers used for first-generation drug-eluting stents
potentially contribute to persistent inflammation and late DES thrombosis. We report
the first in human experience with the rapamycin-eluting biodegradable polymer coated
cobalt-chromium FIREHAWK (MicroPort Medical, Shanghai, China) stent with
abluminal groove.
Methods: Patients with stable or unstable angina, or prior myocardial infarction (MI),
with single de novo native coronary stenosis < 30mm in length in vessel sizes ranging
from 2.25 to 4.0 mm were enrolled at a single institution. The primary endpoint was
major adverse cardiac events (MACE) at 30-day defined as the composite of cardiac
death, MI (Q and non-Q), or ischemia-driven target lesion revascularization. Secondary
endpoints include 4 and 13 months in-stent late lumen loss by quantitative coronary
angiography, proportion of uncovered or malapposed stent struts by Optical Coherence
Tomography (OCT) at 4-month, and MACE at 4, 12, 24 and 36-month follow-up.
Results: A total of 21 patients (age 56.2±8.9 years, male 66.7%, diabetes 14.3%) were
enrolled consecutively in 1 month. The average baseline reference vessel diameter is
2.88±0.51 mm and the lesion length is 17.7±6.1 mm. There was no MACE at 30-day.
One patient died of non-cardiac hemorrhagic stroke 5 days after index procedure. 19
patients at 4-month and 14 patients at 13-month underwent angiographic follow-up,
respectively. The in-stent late loss was 0.13±0.18 mm at 4-month, and 0.16±0.07 mm
at 13-month. There was no binary restenosis. The complete strut coverage was 96.2%
by OCT with only 0.1% strut malapposition at 4-month among 11551 analyzed struts.
There was no MACE at 12-month.
Conclusion: The preliminary feasibility and safety of FIREHAWK stent are
demonstrated in the first in human study. OCT findings indicated excellent stent strut
coverage 4 months after implant. Further pivotal randomized trial will confirm if this
early results could translate into longer term safety and efficacy benefits.
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